Skip to main content
SpringerLink
Log in

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Brequinar (DUP 785; NSC 368390) is a quinoline carboxylic acid derivative that inhibits pyrimidine synthesis at the level of dihydro-orotate dehydrogenase and revealed synergy with cisplatin in preclinical models. In this study investigating the pharmacokinetic and toxicity of brequinar in combination with cisplatin, patients were initially treated with weekly brequinar, in combination with an every-three-week administration of cisplatin. Due to toxicity, the schedule was modified to a 28-day cycle with brequinar given on days 1, 8, 15, and cisplatin on day 1. A total of 24 patients (16 male, 8 female; median age 57; median performance status 1) received 69 courses of therapy. Six dose levels were explored, with cisplatin/ brequinar doses, respectively, of 50/500, 50/650, 50/860, 60/860, 75/650, and 75/860 mg/m2. The serum concentration versus time curves for brequinar were biphasic. A comparison of the pharmacokinetic results after the first and third doses of brequinar indicate that the presence of 50, 60, and 75 mg/m2cisplatin did not change the protein binding and the pharmacokinetics of brequinar in any of the three brequinar-dose groups. Total cisplatin plasma pharmacokinetic followed a triphasic-shape curve and unbound cisplatin decayed at a very rapid rate. Since pharmacokinetic parameters for total cisplatin in this study were similar to those reported in the literature, the presence of brequinar is unlikely to alter the pharmacokinetics of cisplatin. Main dose-limiting toxicities included myelosuppression (including neutropenia and thrombocytopenia) and mucositis. Cisplatin/brequinar doses of 50/500, 50/650, 50/860, 60/860, 75/650, and 75/860 mg/m2, were associated with dose limiting toxicity in 0/3, 1/3, 1/3, 1/3, 2/4, 2/5, and 4/6 patients, respectively. This study shows that co-administration of brequinar and cisplatin does not affect the pharmacokinetic properties of either drug and that the MTDs of cisplatin/brequinar combinations are 60/860 mg/m2 or 75/650 mg/m2. From this study, we conclude that full dose of 75 mg/m2 cisplatin (day 1) can be administered with 650 mg/m2 brequinar (days 1, 8 and 15) without significant modifications of individual drug pharmacokinetic parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dexter DL, Hesson DP, Ardecky RJ, Rao GV, Tiffett DL, Dusak BA, Paull KD, Plowman J, Delarco BM, Narayanan VL, Forbes M: Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1, 1'-biphenyl-4-YL)-3-methyl-4-quinolinecarboxylic acid sodium salt], against experimental tumors. Cancer Res 45: 5563-5568, 1985.

    Google Scholar 

  2. Chen S-F, Ruben RL, Dexter DL: Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1, 1'-biphenyl-4-YL)-3-methyl-4-quinolinecarboxylic acid sodium salt (NSC 368390): inhibition of de novopyrimidine nucleotide biosynthesis. Cancer Res 46: 5014-5019, 1986.

    Google Scholar 

  3. Peters GJ, Sharma SL, Laurensse E, Pinedo HM: Inhibition of pyrimidine de novosynthesis by DUP 785 (NSC 368390). Invest New Drugs 5: 235-244, 1987.

    Google Scholar 

  4. Schwartsmann G, Peters GJ, Laurensse E, de Waal F, Loonen A, Leyua A, Pinedo H: DUP 785: Schedule-dependency of growth inhibitory and antipyrimidine effects. Biochem Pharmacol 37: 3257-3266, 1988.

    Google Scholar 

  5. de Forni M, Chabot GG, Armand JP, Fontana X, Recondo G, Domenge C, Carde P, Barbu M, Gouyette A: Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients. Eur J Cancer 29A: 983-988, 1993.

    Google Scholar 

  6. Schwartsmann G, Dodion P, Vermorken JB, ten Bokkel Huinink W, Joggi J, Winograd B, Gall H, Simonetti G, Van der Vijgh W, Van Hennick M: Phase I study of brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother Pharmacol 25: 345-351, 1990.

    Google Scholar 

  7. Bork E, Vest S, Hansen HH: A phase I clinical and pharmacokinetic study of brequinar sodium (DUP 785; NSC 368390), using a weekly and a bi-weekly schedule. Eur J Cancer Clin Oncol 25: 1403-1411, 1989.

    Google Scholar 

  8. Currie V, O'Hehir M, Baltzer L, Slavik W, Yaldaei S, Bertino J: Phase I trial of DUP 785 given on a single weekly intravenous dosing schedule. Proc Am Soc Clin Oncol 4: 76, 1988.

    Google Scholar 

  9. Fischer DS, Tish Knobf M, Durivage HJ: The Cancer Chemotherapy Handbook Ed4. Mosby Yearbooks, St. Louis, 1993, pp 79-82.

    Google Scholar 

  10. Braakhuis BJ, van Dongen GA, Bagnay M, van Walsum M, Snow GB. Preclinical chemotherapy on human head and neck cancer xenografts in athymic mice. Head and Neck 11(6): 511-515, 1989.

    Google Scholar 

  11. Chen S-F, Dexter DL: Preclinical studies with brequinar sodium: A novel anticancer agent. In: Valeriote FA, Corbett TH, Baker LH (eds) Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Kluwer Academic Publ, Norwell, MA, 1992, pp 261-280.

    Google Scholar 

  12. Arteaga C, Brown T, Kuhn J, Shen H: Phase I clinical and pharmacokinetic trial of brequinar sodium (DUP 785; NSC 368390). Cancer Res 49: 4648-4653, 1989.

    Google Scholar 

  13. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics, Ed. 3. Lea and Febiger, Philadelphia, 1984, pp 17-18.

    Google Scholar 

  14. Lamm FC, Hung CT, Perrier DG: Estimation of variance for harmonic mean half-lives. J Pharm Sci 74: 229-231, 1985.

    Google Scholar 

  15. Chen JJ, Jones ME: The cellular location of dihydroorotate dehydrogenase: relation to de novo biosynthesis of pyrimidines. Arch Biochem Biophys 176: 82-90, 1976.

    Google Scholar 

  16. Jones ME: Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu Rev Biochem 49: 253-279, 1980.

    Google Scholar 

  17. Peters GJ, Schwartsmann G, Nadal JC, Laurensse EJ, Van Groeningen CJ, Van der Vijgh WJF, Pinedo HM: In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP 785; NSC 368390) in mice and patients. Cancer Res 50: 4644-4649, 1990.

    Google Scholar 

  18. Pizzormo G, Wiegand RA, Lentz SK, Handschumacher RE: Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools. Cancer Res 52: 1660-1665, 1992.

    Google Scholar 

  19. Buzaid AC, Pizzorno G, Marsh JC, Ravikumar TS, Murren JR, Todd M, Strair RK, Poo WJ, Hait WN: Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study. Cancer Chemother Pharmacol 36(5): 373-378, 1995.

    Google Scholar 

  20. Noe DA, Rowinsky EK, Shen HSL, Clarke BV, Grochow LB, McGuire WB, Hantel A, Adams DB, Abeloff MD, Ettinger DS, Donehower RC: Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). Cancer Res 50: 4595-4599, 1990.

    Google Scholar 

  21. Dodion PF, Wagener T, Stoter G, Drozd A, Lev LM, Skovsgaard T, Renard J, Cavalli F: Phase II trial with brequinar (DUP 785; NSC 368390) in patients with metastatic colorectal cancer: A study of the early clinical trials group of the EORTC. Ann Oncol 1: 79-80, 1990.

    Google Scholar 

  22. Cody R, Stewart M, de Forni M, Moore M, Dallaire B, Azarnia N, Gyves J: Multicenter phase II study of brequinar sodium in patients with advanced breast cancer. Am J Clin Oncol 16(6): 526-528, 1993.

    Google Scholar 

  23. Moore M, Maroun J, Robert F, Natale R, Neidhart J, Dallaire B, Sisk R, Gyves J: Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancers. Invest New Drugs 11(1): 61-65, 1993.

    Google Scholar 

  24. Natale R, Wheeler R, Moore M, Dallaire B, Lynch W, Carlson R, Grillo-Lopez A, Gyves J: Multicenter phase II trial of brequinar sodium in patients with advanced melanoma. Ann Oncol 3: 659-660, 1992.

    Google Scholar 

  25. Maroun J, Ruckdeschel J, Natale R, Morgan R, Dallaire B, Sisk R, Gyves J: Multicenter phase II study of brequinar sodium in patients with advanced lung cancer. Cancer Chemother Pharmacol 32(1): 64-66, 1993.

    Google Scholar 

  26. Urba S, Doroshow J, Griffs C, Robert F, Velez-Garcia E, Dallaire B, Adams D, Carlson R, Grillo-Lopez A, Gyves J: Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck. Cancer Chemother Pharmacol 31: 167-169, 1992.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brooke Army Medical Center (BAMC), Fort Sam Houston, Texas

    Howard A. Burris III, Timothy J. O'Rourke & Daniel D. Von Hoff

  2. The University of Texas Health Science Center at San Antonio, Texas, ???

    Howard A. Burris III & John G. Kuhn

  3. Cancer Therapy and Research Center of South Texas, San Antonio, Texas, ???

    Howard A. Burris III, Eric Raymond & Daniel D. Von Hoff

  4. Department of Medicine, Institute Gustave-Roussy, Villejuif, France

    Eric Raymond

  5. Unité de Chimiothérapie, Service de Médecine, Institut Jules Bordet, Bruxelles, Belgium

    Ahmad Awada

  6. DuPont Merck Pharmaceutical Company, Barley Mill Plaza, Wilmington, Delaware, ???

    James Brentzel, William Lynch & Shang-Ying P. King

  7. Duke University Medical Center, Durham, North Carolina, U.S.A

    Thomas D. Brown

Authors
  1. Howard A. Burris III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Raymond
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmad Awada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John G. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Timothy J. O'Rourke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James Brentzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shang-Ying P. King
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burris, H.A., Raymond, E., Awada, A. et al. Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies. Invest New Drugs 16, 19–27 (1998). https://doi.org/10.1023/A:1016066529642

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016066529642

Search

Navigation